2 active alerts Show

Insights & Innovations - General Surgery

The latest advancements and breakthroughs in general surgery

Summer 2026 Issue

Cornea and cataract surgeon Tony Thieu, M.D., arrived at ChristianaCare in spring 2026 and brought with him specialty training in state-of-the-art procedures for corneal transplant.

One procedure, called Descemet membrane endothelial keratoplasty (DMEK), is a form of corneal transplant in which a thin layer of dysfunctional endothelial cells in the cornea of the eye is replaced with healthy donor tissue. The approach is used to treat corneal tissue damage that occurs as a result of endothelial injury from prior eye infections, trauma, or ocular conditions such as Fuchs’ dystrophy. It is also used in patients who experience complications from prior eye surgery, including cataract removal and glaucoma procedures.

“DMEK is a newer type of corneal transplantation that uses a thinner graft than other endothelial transplant approaches,” Dr. Thieu said. “Because of that, we are seeing better visual outcomes with the procedure and there is also a lower risk for tissue rejection.”

A side-angle closeup of an eye

Like all forms of corneal transplant, or keratoplasty, DMEK uses tissue gifted from deceased human donors. Because ChristianaCare partners with local and national eye banks, there is typically no waitlist for patients undergoing DMEK and other corneal transplants, as there may be for other organ transplant procedures.

When successful, DMEK can restore vision, relieve pain, and improve the appearance of the eye in patients with corneal damage, according to Dr. Thieu. In a systematic analysis published in 2017, DMEK was found to be superior to another transplant procedure, Descemet stripping automated endothelial keratoplasty (DSAEK), for postoperative visual acuity, central corneal thickness, and patient satisfaction. Mean spectacle-corrected visual acuity at 6 months was better for DMEK than DSAEK and all cases showed similar and significant improvements in patients’ endothelial cell density (the volume of specialized cells in the innermost layer of the cornea that are required for maintaining transparency) post-transplant.1

“Whether a patient is eligible for DMEK depends on the complexity of the eye in each case,” he said. “Patients who have had prior ocular surgery, such as a vitrectomy, or who have other ocular comorbidities like glaucoma may not be a good candidate for DMEK. For these patients, we can use DSAEK or another type of keratoplasty.”

Most of the patients Dr. Thieu evaluates and treats are referred to him by community optometrists or primary care physicians after they complained of vision problems or presented with signs of ocular inflammation, including pain. Dr. Thieu hopes to treat patients before their tissue damage has progressed significantly; hence, early diagnosis of the underlying cause of the damage is key.

In addition to treating patients who have suffered corneal tissue damage during cataract removal, Dr. Thieu will also treat patients deemed to be at risk for the complication. For these patients, he will perform the cataract removal first, taking specialized measures to protect the cornea. If corneal tissue injury results, he will treat with a subsequent transplant.

For most corneal transplant procedures, operating time is about 60 minutes. All procedures are done on an outpatient basis, under anesthesia, although recovery times vary. Vision begins to return within 48 hours, but the process may take up to one month. Patients are typically advised to “lie flat for about a week” after the procedure, Dr. Thieu said.

For patients who have had significant scarring from prior infections or injury to the cornea, Dr. Thieu offers full-thickness transplants (penetrating keratoplasty) or a more specialized procedure called deep anterior lamellar keratoplasty (DALK). DALK involves replacing only the anterior 95% of the cornea while leaving its healthy innermost layer, the endothelium, intact.

“Very few cornea surgeons offer DALK given the delicate nature, specialized training, and time intensity of the procedure,” Dr. Thieu said. “If successful, this leads to lower rejection risk and less reliance on eyedrops over the lifetime of the transplanted cornea.”

With all transplants, follow-ups are scheduled for the day after the procedure and one week later to assess efficacy and recovery.

“Our multidisciplinary team is with our patients for the long haul to ensure success and full recovery, and there are plenty of options for complex cases,” Dr. Thieu said. “With the aging population in Delaware, the types of eye diseases and disorders that may necessitate corneal transplant are increasingly common. That’s why the eye care services we offer at ChristianaCare will have a significant impact on our community.”

Reference

1. Cornea. 2017;36(11):1437-1443.

Obesity is a chronic, complex disease, and it’s one that needs sustained, multidisciplinary support.

At ChristianaCare’s Center for Weight Management (CWM), an integrated team of obesity medicine specialists, bariatric surgeons, registered dietitians, and behavioral health professionals is bringing all of those resources together under one roof, with a coordinated approach designed to meet patients wherever they are on the treatment spectrum.

A woman in exercise-wear sites on a trail drinking from a water bottle, as her dog stands next to her

“Obesity management is a spectrum,” said obesity medicine specialist Lisa Breslow, D.O. “We have medications, we have surgery, and oftentimes we need both. The treatment of obesity is very individualized—different for every person. Patients shouldn’t assume, ‘I took Ozempic [semaglutide, Novo Nordisk] and now my weight struggles are gone forever.’ Obesity is a chronic relapsing and remitting disease that requires ongoing treatment. When we work together to develop the best plan to treat obesity, our patients have the best chance for long term success.”

The CWM’s newly unified structure brings together two previously separate tracks—obesity medicine and bariatric surgery—into a single, cohesive program. Patients who are candidates for bariatric surgery, or who are interested in exploring it, begin with a free virtual seminar that provides an overview of the surgical options, the preparation process, and what to expect. Surgery is as safe and well-tolerated as other common procedures, including knee replacement and cholecystectomy, according to ChristianaCare fellowship-trained bariatric surgeon Elizabeth Gareau McCarthy, M.D.

Those who prefer to start with medication management, or who do not qualify for surgery, work with Dr. Breslow or one of the program’s nurse practitioners through a structured one-year intensive program that includes regular (usually monthly) touchpoints with both medical providers and dietitians throughout the process.

The integration of the two tracks means patients can move fluidly between them as their needs evolve.

“There are some instances when patients try anti-obesity medications and they are unable to achieve a targeted goal weight,” Dr. Breslow explained. “At the Center for Weight  management, the integration of the two treatment tracks allows for a seamless transition to explore the surgical options that the bariatric surgeons have to offer.”

On the surgical side, Dr. McCarthy and her colleagues offer the full spectrum of proven bariatric procedures, including gastric sleeve, gastric bypass, and revisional surgery, using minimally invasive laparoscopic and robotic-assisted techniques. The program is accredited by the American Society for Metabolic and Bariatric Surgery and recognized by Optum’s Centers of Excellence network.

After surgery, patients are supported by the surgical team and nurse practitioners through a structured follow-up program that continues for up to five years, at which point stable patients transition back to primary care.

Before any patient proceeds to surgery, ChristianaCare’s Center for Surgical Optimization conducts a thorough medical evaluation that includes reviewing health history in detail, screening for undiagnosed conditions, and coordinating with relevant specialists to ensure every patient is as safe as possible on the operating table.

“They really go through the patient’s history with a fine-tooth comb,” Dr. McCarthy said.

Sleep apnea, she noted, is one of the most consequential findings. It’s common among patients with obesity, often undiagnosed, and potentially dangerous in the surgical setting if not addressed.

“If somebody has moderate to severe sleep apnea and needs a CPAP [continuous positive airway pressure] machine, it’s not safe to do surgery unless they’ve gotten that machine and they’re using it appropriately.”

Other complex comorbidities, ranging from hemophilia requiring hematology consultation to poorly controlled hypertension or cardiac issues, are identified and optimized before a surgical date is set.

Screening at the CWM goes beyond physical health. Dr. Breslow, who spent years in primary care before focusing on obesity medicine, emphasized the importance of evaluating patients for eating disorders that are often overlooked in traditional clinical settings.

“When people think about eating disorders, they think about anorexia or bulimia,” she said. “However, there are other eating disorders that impact a patient’s weight-loss journey, such as binge eating disorder or night eating syndrome. It is imperative to ensure we address all factors, from both a medical and psychological standpoint, so the patient can be maximally successful.”

Both Drs. Breslow and McCarthy emphasized that the CWM is designed to function as an extension of, not a replacement for, the primary care relationship.

Dr. Breslow, drawing on her own background in family medicine, described obesity as a condition that is simply too complex to address adequately in a standard office visit.

“It’s impossible to adequately address all the factors at play for a patient who struggles with obesity in a 15-minute time slot,” she said. “We can take that burden off primary care physicians and help their patient in a comprehensive way.”

Breast reconstruction can be an essential step in recovery after mastectomy, one that extends beyond physical restoration to encompass emotional and psychological wellbeing.

“For breast cancer, offering breast reconstruction is the standard of care,” said Stephanie Caterson, M.D., a plastic surgeon who specializes in comprehensive breast reconstruction. “Offering the full breadth of reconstructive options is essential to serve our community, including state-of-the-art nipple and areola restoration tattooing techniques.”

Dr. Caterson founded the Center for Reconstructive Plastic Surgery at Christiana Care in 2019 and has grown the practice to include multiple specialty-trained clinicians, including Kerry Gregory, PA-C.

A Stepwise, Personalized Approach

At ChristianaCare, the reconstructive plastic surgery team helps patients make the choices that are right for them. Breast reconstruction is carefully tailored to each patient’s clinical needs, cancer treatment plan, and personal goals.

Dr. Caterson and Gregory work closely with surgical, medical, and radiation oncologists to guide patients through their options, beginning with an in-depth consultation prior to surgery. For those who choose reconstruction, multiple procedures are usually necessary, with timing influenced by chemotherapy or radiation requirements. When preservation of the nipple and areola complex is not possible during the mastectomy, modern reconstruction techniques can recreate its form and appearance, restoring the natural breast contour.

After the breast mound has been reconstructed, there are two main approaches to recreating the nipple-areola complex. One option involves a short office-based procedure to surgically create a projecting nipple, typically followed by tattooing several months later, once healing is complete. The alternative is to forgo the surgical nipple creation and proceed directly to tattooing. With advanced tattooing techniques, a highly realistic three-dimensional nipple-areola complex can be achieved without the physical projection of the nipple.

“The choice to pursue nipple-areola complex reconstruction is very individual, and we try to provide as much guidance as possible for women so that they can make educated decisions,” Dr. Caterson noted.

Before-and-after photographs help illustrate the different options and expected outcomes. Patients can try temporary tattoos to preview how a tattooed areola might look and can apply an adhesive silicone nipple-areola complex device to visualize the anticipated appearance of a projecting nipple in combination with tattooing.

Reconstruction and the Science of Well-Being

“Breast cancer treatment involves so much more than just the physical changes that occur in the body; it can be very emotional, mental and sometimes spiritual,” said Gregory, who works closely with Dr. Caterson and specializes in 3D tattooing. “We try to heal the whole patient and, given that many women tie their identity to their breasts, their hair, their nails, and other aspects of their appearance that may be altered during treatment, it’s very easy to think, ‘I’m not the same person,’ until you get some of that back.”

A growing body of research highlights the importance of breast reconstruction in improving quality of life after mastectomy. Studies from Memorial Sloan Kettering Cancer Center using the validated BREAST-Q demonstrate significant improvements in patient satisfaction, body image, psychosocial well-being, and sexual health following reconstruction.1,2 Completion of the nipple-areola complex has also been associated with increased satisfaction and a greater sense of closure at the end of the reconstruction process.3,4

The Final Step: Restoring a Sense of Wholeness

Nipple and areola tattooing is a noninvasive procedure that uses advanced shading, custom color blending, and specialized artistic techniques to create the illusion of a realistic, three-dimensional nipple-areola complex.

Gregory begins the process by carefully mapping and measuring the reconstructed breast, working closely with each patient to determine the optimal size, shape, and position for their tattoo. Precision pigmentation is then used to match skin tone and achieve a natural, symmetrical result. More than 90% of patients who undergo breast reconstruction at ChristianaCare elect to pursue this final step of nipple-areola complex recreation with Gregory’s tattooing process.

“The skill and expertise of our reconstructive microsurgeons at ChristianaCare are unmatched. They are just phenomenal,” Gregory said. “My role is to complement their work and give our patients a sense of normalcy and a feeling that there is life after breast cancer. We truly believe all our patients should be able to live their best lives, and that means being comfortable with the appearance of their bodies.”

Within the continuum of breast cancer care, reconstruction represents more than a procedure: it is a forward-looking step toward survivorship. At ChristianaCare, that vision remains clear: to support patients not only in overcoming cancer, but in reclaiming their identity, confidence, and well-being.

References

1. Plast Reconstr Surg. 2009;124(2):345-353.
2. Cancer. 2012;118(6):1701-1709.
3. N Engl J Med. 2008;359(15):1590-1601.
4. Plast Reconstr Surg. 2002;110(2):457-463.

Hiatal hernias are among the most common anatomic findings in adults, occurring in anywhere between 10% and 50% of people in the United States. Most are small, asymptomatic, and appropriately managed with medication alone. However, a meaningful subset of patients will benefit from surgical consultation.

At ChristianaCare, general surgeon Anthony Tascone, M.D., and his colleagues offer the full spectrum of minimally invasive repair options for hiatal hernias, along with the preoperative workup and newer diagnostic technologies that help match each patient to the right procedure.

“About 95% of hiatal hernias are sliding hiatal hernias, small hernias where the upper portion of the stomach slides above the diaphragm,” Dr. Tascone said. “The other 5% are larger hiatal hernias, or paraesophageal hernias, which will typically be a little bit more symptomatic.”

When sliding hiatal hernias make themselves known symptomatically, it’s most often through gastroesophageal reflux symptoms, particularly heartburn and regurgitation. These patients are typically treated first with medications, Dr. Tascone said. Surgery becomes a good option when symptoms aren’t controlled medically, or when regurgitation is the dominant complaint.

Paraesophageal hernias—larger defects where more of the stomach, and sometimes other abdominal contents, can herniate into the chest—warrant a different conversation.

“In the past, surgery was typically recommended to all patients with larger hiatal hernias or paraesophageal hernias, unless they were a very high surgical risk,” Dr. Tascone said. “That recommendation has softened over time. It’s now a discussion to be had, but not everyone who has an asymptomatic paraesophageal hernia requires surgery.”

That said, he pointed to a 2024 analysis showing that elective laparoscopic repair of asymptomatic paraesophageal hernias is associated with gains in life expectancy compared with watchful waiting across ages 40 to 90 years.1 Elective repair beat watchful waiting in both sexes, but the life-years gained were larger in women than in men at every age, with the largest projected benefit in younger women (up to 2.6 life-years in the youngest cohort modeled) and diminishing gains with increasing age. The analysis updates a two-decade-old model that had recommended observation and reflects both the improved safety of modern laparoscopic repair and the ongoing risk that an untreated hernia will eventually require emergency surgery.

“Primary care physicians may see ‘hiatal hernia’ on a CAT scan report and not think anything of it,” Dr. Tascone said. “But if it’s a large hiatal hernia, those are really patients that should have a conversation with a surgeon.”

Younger patients have better long-term outcomes and tolerate any rare complications more easily than those in their 70s and beyond, he added.

Compared with 10 or 15 years ago, surgical options for hiatal hernia have evolved significantly. The core of the operation remains the same: Dissect the stomach out of the chest, return it to the abdominal cavity, close the hernia with permanent sutures (with or without absorbable mesh), and perform an antireflux procedure for patients whose primary issue is reflux.

What has changed is the choice of antireflux procedure. The classic Nissen fundoplication (a full 360-degree wrap of the upper stomach around the lower esophagus to create a new valve) is starting to fall out of favor, according to Dr. Tascone.

“Most surgeons, including myself, are typically doing partial wraps, 270 degrees or 180 degrees, which seem to have similar antireflux mechanisms with fewer postsurgical issues,” he said. “The full wrap still remains a legitimate option depending on patient characteristics, however.”

The most notable short-term trade-off of the full wrap is dysphagia (feeling of food not passing through the wrap), which typically improves over time but is seen less often with partial wraps.

A second option that has gained ground is the LINX device, a ring of magnetic beads placed around the lower esophagus that opens to allow food passage and then closes to prevent reflux.

“LINX has shown similar long-term reflux prevention as fundoplication in appropriately selected patients with the proper workup,” Dr. Tascone said.

Before offering either a full fundoplication or a LINX device (Johnson & Johnson)—any procedure that places a 360-degree construct around the lower esophagus—the esophagus itself needs to be shown to function well. The traditional tool for this is esophageal manometry, in which a probe placed through the nose assesses how well the esophageal muscles push a fluid bolus downward. Patients who don’t generate adequate pressure risk being unable to push food through a full wrap or LINX. Manometry is uncomfortable, and for patients who are good candidates for a partial wrap, it can often be avoided entirely.

For patients who need further evaluation, ChristianaCare offers two additional endoscopic tools. EndoFLIP (Endoluminal Functional Lumen Imaging Probe; Medtronic), acquired in recent years, provides data on esophageal function similar to manometry but through an endoscopic approach, and can be used intraoperatively to give real-time feedback on the tightness of a fundoplication, helping ensure the wrap is tight enough to reduce reflux but loose enough to allow food and drink to pass. Bravo pH testing, also done endoscopically, leaves a probe in the lower esophagus to confirm pathologic reflux in patients whose heartburn isn’t controlled with medication alone, ensuring that those being sent to surgery are the ones most likely to benefit.

All hiatal hernia repairs at the ChristianaCare are performed using minimally invasive laparoscopic or robotic-assisted techniques.

With robotic technology, even patients who have had prior upper abdominal surgery or multiple prior operations elsewhere in the abdomen can be approached minimally invasively.

“We typically can figure out a way to safely get into the abdomen, clear out any scar tissue, and perform the surgery through minimally invasive techniques,” Dr. Tascone said, noting that open surgery for hiatal hernia is now extraordinarily rare.

Hospital stays have also shortened substantially. Most patients are discharged to home one or two days after surgery, followed by a structured diet—typically liquids or soft foods for about a week, with most patients advancing to a normal diet over roughly a month. The LINX device has a distinctive postoperative dietary protocol: Patients are asked to eat something semisolid or solid every hour or two to keep the magnetic beads opening and closing during the early healing period.

Referrals from within ChristianaCare are made through the General Surgery Clinical Collaboration (CLINC), with “hiatal hernia” or “paraesophageal hernia” entered in the reason for consultation, according to Dr. Tascone. Most patients arrive with imaging (often a CAT scan or endoscopy that identified the hernia), although imaging will be ordered when needed, particularly for complex or recurrent cases. Urgent surgery for hiatal hernia is rare, he noted, but ChristianaCare surgeons can accommodate prompt evaluation when clinically appropriate. Patients can generally be seen in the office within one to two weeks.

“Our team typically will reach out to that patient within a day or two of receiving the CLINC,” he added.

Reference

1. Ann Surg. 2024;279(2):267-275.

For patients with liver tumors who are not surgical candidates, or who need to continue chemotherapy without interruption, ChristianaCare now offers histotripsy: the complete, noninvasive destruction of liver tumors using precisely focused ultrasound waves, with no cutting, radiation, or needles.

ChristianaCare is the first health system in Delaware and the first in the Philadelphia region to offer the technology, making it a destination for patients who may otherwise have had no local options.

Surgical oncologists Arvind Sabesan, M.D., and Brendan Hagerty, M.D., have been the driving force behind bringing HistoSonics’ FDA-cleared Edison® System for histotripsy to ChristianaCare, and they see it as a meaningful expansion of what the health system can offer to patients.

“It opens up a whole panel of patients that may not have been eligible for other more invasive treatments,” Dr. Sabesan said. “People who were thought to be too sick for treatment, people who may not have wanted surgery, people with many liver lesions that the treating physician thought were too many to treat—now we can treat them.”

Histotripsy uses high-intensity focused ultrasound to generate controlled acoustic cavitation: microscopic bubbles that rapidly expand and collapse within targeted tissue, mechanically destroying cells at a subcellular level without generating heat. Unlike thermal ablation, which burns tissue, histotripsy works purely through mechanical disruption, which means it can treat tumors near critical structures like blood vessels and bile ducts without the risk for thermal damage to the surrounding anatomy.

“Just like an opera singer is able to shatter a wineglass using a very high-frequency voice, histotripsy uses a similar principle,” Dr. Sabesan explained. “Focused ultrasound waves create aggressive mechanical disruption at a single point, the size of a grain of rice. We map out the tumor in three dimensions, and the system moves around it in multiple passes, like a 3D printer, completely destroying the entire tumor.”

The procedure is performed under general anesthesia, with the patient immobilized to ensure precision during treatment. The computer calculates treatment time based on the 3D tumor map; for many cases, the active treatment phase takes roughly less than one hour. Tumor destruction is monitored in real time under continuous ultrasound visualization.

Because there is no incision and no sterile field to maintain, the procedure is logistically straightforward for the operating room team. Patients typically stay overnight for monitoring, IV hydration, and laboratory checks, and go home the following day.

FDA clearance for the Edison System was granted in October 2023, based on data from the #HOPE4LIVER pivotal trials, a prospective, international, multicenter, single-arm program conducted across 13 sites in the United States, the United Kingdom, and Europe. The trials enrolled 44 patients with primary and metastatic liver tumors spanning a heterogeneous range of diagnoses, including hepatocellular carcinoma and metastatic disease from colorectal, breast, and other primary cancers.

Technical success, defined as precise targeting and destruction of the tumor with adequate margin, was achieved in 42 of 44 treated tumors (95.5%), exceeding the prespecified performance goal of 70%. Procedure-related major complications occurred in three of 44 patients (6.8%), meeting the trial’s safety end point.1

Since clearance, the Edison System has been used to treat more than 4,000 patients worldwide. One-year follow-up data suggest tumor control rates comparable to current standard-of-care locoregional therapies.

Histotripsy is FDA approved for any liver tumor, primary or metastatic, but patient selection within that broad indication remains nuanced. Today’s ideal candidates, Dr. Sabesan said, include patients who are not good surgical candidates for medical reasons, patients who cannot stop anticoagulation therapy, those with multiple liver lesions who would otherwise require a major operation, and those who need to return to systemic chemotherapy quickly without the recovery delay imposed by open surgery.

“They would receive histotripsy as an outpatient, and go home the same day or the next day,” he said. “They don’t have to stop any of their blood thinners, and they can continue on with their chemotherapy or other treatment the following week. So, it involves very minimal delay in other cancer treatment.”

Clinical trials are underway evaluating histotripsy for kidney tumors (#HOPE4KIDNEY), pancreatic adenocarcinoma, and other solid malignancies. Early preclinical and translational data also suggest that histotripsy may stimulate an antitumor immune response.

Still, Dr. Sabesan is candid about the state of the evidence: Long-term comparative data against surgical resection do not yet exist.

“We tell patients that it’s a new technology and its FDA approved but we need time to gather long term data” he said. “And we make clear that by offering this as a treatment, it does not take away any other treatment options.”

ChristianaCare’s position as the only program in Delaware and the Philadelphia region to offer histotripsy has already begun to generate referral interest beyond the health system’s traditional catchment area. Patients are actively seeking out the technology through social media and patient community networks, Dr. Sabesan noted.

As the program scales up, he anticipates treating up to 10 patients per month once fully operational.

“One of the patients who came to see us found it on Twitter and wanted to come and get treated,” he said.

Reference

1. Radiology. 2024;312(3):e233051.

Fall 2025 Issue

Without proper care, chronic wounds can lead to serious complications, including infection, amputation and prolonged disability. At ChristianaCare’s Wound Care & Hyperbaric Medicine Center, specialists use advanced technologies and hyperbaric oxygen therapy to help patients heal.

“The Wound Care Center is a place where we utilize our expertise to focus on healing wounds,” said James Ley, M.D., a wound care and infectious diseases specialist at ChristianaCare. “We have a variety of specialized products for wounds available to us. We are very careful to establish a clear-cut etiology for a wound, and we try to address any obstacles to healing.”

Patients with wounds may initially present to their primary care doctor, who may not have the resources or equipment to adequately support healing. The Center is a specialized resource to meet patients’ needs when routine care is not enough, and we have fairly tight protocols. We see patients on a regular basis, we used an advanced technology to measure wounds and determine the composition of tissue in the wound, to know patients healing progress. Our goal is to heal all of our wounds within 12 weeks or so.”

The Wound Care Center treats a wide range of conditions, including venous stasis ulcers, diabetic foot ulcers, pressure injuries and complex traumatic wounds. Dr. Ley recommends referral for wounds that don’t heal within 30 days of routine care or have the potential to become chronic.

Treatment at the Wound Care Center is highly individualized to identify and remedy underlying causes and barriers to healing. The Center deploys specialized wound care products, from dressings that manage drainage, to collagen-based products that promote tissue growth, to antimicrobial dressings that protect against infection.

In addition, Cellular tissue products (CTP’S) are a biological or synthetic material used to treat wounds, especially those that are difficult to heal, by mimicking the structure and function of human skin. These products can be derived from human or animal sources and may contain viable or non-viable cells. They are designed to promote wound closure, reduce inflammation and improve tissue regeneration, and they represent some of the newest innovations in wound care technology.

“We continue to utilize new products as they become available if we think they will give us an advantage,” Dr. Ley said.

Patients treated at ChristianaCare also have access to hyperbaric oxygen therapy. This treatment places patients in pressurized chambers where they receive 100% oxygen. This high pressure forces oxygen to dissolve into the blood, allowing increased delivery to tissues where it promotes healing, reduces inflammation and helps fight infection.

The therapy is particularly effective for radiation-induced injuries, including radiation cystitis or delayed wound healing in patients who have received radiation treatment for breast or prostate cancer. Patients with radiation damage to the jaw, teeth or mouth tissues from treatment for head and neck cancer also benefit significantly from hyperbaric oxygen treatment.

 “We’re able to apply hyperbaric oxygen therapy to those situations, and we see fairly good results,” Dr. Ley said. “We’ve seen function improve significantly, where people are hardly able to eat, but after treatment, can actually begin to eat again and chew food.”

ChristianaCare’s Wound Care Center uses a multidisciplinary approach to wound healing, with access to many specialists in vascular surgery, plastic surgery, general surgery, podiatry and infectious disease. This comprehensive team ensures that the underlying causes of wounds are properly addressed, not just the surface symptoms, so patients can heal quickly.

“In our area, we’re the main provider for this kind of care,” Dr. Ley said. “We have a lot of depth in being able to deal with the underlying causes of wounds.”

The recent addition of a hybrid OR suite at the ChristianaCare Center for Heart and Vascular Health has enabled surgeons to transform the care offered to patients with complex cases, allowing for surgeries that just months ago wouldn’t have been possible.

The room—housed within the Gerret and Tatiana Copeland Heart and Vascular Interventional Suites—features built-in capabilities for x-ray, fluoroscopy and CT scans, and it enables procedures that combine traditional open surgery and minimally invasive techniques.

“It’s very advanced equipment that allows us to do things that we couldn’t do before,” said Kathryn Bowser, M.D., a vascular surgeon and one of the founding physicians of the ChristianaCare Center for Aortic Health. “It allows us to treat some extremely complex disease processes.”

“Without a doubt, the suite allows us to do procedures that would not have been a possibility before,” added vascular surgeon Mikael Fadoul, M.D. “The integrated fusion technology has really enhanced our ability to treat complex aortic pathology, specifically thoracoabdominal aneurysms.”

Since opening in February 2025, the room has been used regularly to treat advanced aortic disease that sometimes used to require transfer to other facilities, such as aortic aneurysms, aortic thrombus and aortic dissection.

“These procedures may have previously required patients to be transferred out of the hospital, or had to be done purely with open surgery,” said Dr. Bowser, who is also site primary investigator for the recently funded multi-institutional trial called WARRIORS, or Women’s Aneurysm Research: Repair Immediately or Routine Surveillance. “Now, if we can do them in a less invasive manner with this advanced technology, we can provide much better outcomes for patients. These are things that just can’t be done any other way. In another OR, you’d have to bring in additional equipment; you can’t see as well. It becomes much more cumbersome. In the new suite, everything is integrated into the room in order to allow us to do these different types of surgeries.”

“The room has allowed us to do custom fenestrated devices for patients who otherwise would not have had an option for minimally invasive repair,” Dr. Fadoul added. “There is nowhere else in the state of Delaware that is doing this, and only a handful of places on the East Coast.”

The Heart and Vascular team at ChristianaCare has also been pioneering procedures for thoracic aortic dissection that reduce the need for open thoracic surgery. In addition, the team was the first in Delaware to use a GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis device, which is the first FDA-approved, off-the-shelf device for treating complex aneurysmal disease involving the visceral aorta.

Meanwhile, the health system leads the region in treatment of aortic pathology. For example, ChristianaCare was the first system in Delaware to perform thoracic branch endograft. The team has also been conducting deep vein arterialization and using innovative systems such as LimFlow and DETOUR, which are used to restore blood flow to the lower limbs in patients suffering from severe critical limb ischemia and peripheral arterial disease.

“ChristianaCare has been at the forefront of getting these technologies brought into the health system in order to allow us to provide the most up-to-date care for otherwise no-option patients,” Dr. Fadoul said.

“We can really expand care to help people in Delaware in a way we have never been able to before,” Dr. Bowser added. “And we couldn’t be doing it without access to a room like the hybrid OR suite.”

Robotic-assisted surgery offers patients precision, improved outcomes and faster recovery. The comprehensive robotic surgery program at ChristianaCare spans multiple specialties, and its experts have performed more than 20,000 operations, establishing the program as a leader in minimally invasive surgery.

The scope of robotic surgery at ChristianaCare spans general surgery, thoracic surgery, urology, colorectal surgery, obstetrics and gynecology, ENT and oncology, making it one of the region’s most comprehensive robotic surgery programs.

“Certainly, within the state of Delaware, our institution offers the widest spectrum of specialties utilizing robotics in surgery,” said Peter Santoro, M.D., Section Chief of General Surgery and Director of Robotic Surgery at ChristianaCare. “It’s a comprehensive healthcare system, where patients can receive whatever type of surgical care they need. In total, we have done, as a system, almost 21,000 robotic operations since the inception of the robotic surgery program.”

Minimally invasive techniques like robotic-assisted surgery offer significant benefits over traditional open and even laparoscopic surgical approaches. By utilizing robotics in surgery, patients experience smaller incisions, faster recovery times, a quicker return to work, reduced postoperative pain and decreased narcotic use.1,2 These advantages translate to improved patient satisfaction and better overall surgical experiences.

The precision afforded by robotics allows surgeons to perform complex procedures through small incisions, and enhanced visualization, improved dexterity and tremor filtration enable surgeons to operate accurately in confined spaces and around delicate structures.

ChristianaCare’s broad robotic surgery capabilities are facilitated by seven state-of-the-art da Vinci (DV) surgical systems. These robotic platforms are manufactured by Intuitive Surgical, a leading medical technology company that pioneered robotic-assisted minimally invasive surgery.

“Earlier this year, we added two new systems to upgrade our fleet from five robots to seven robots,” Dr. Santoro explained. The recent addition of two new DV5 systems, the newest model offered by Intuitive, is the latest advancement in ChristianaCare’s robotic service offerings.

The seven robotic systems are strategically distributed across the health system, with five Xi models at Christiana Hospital—four in the main operating rooms and one in the surgery center—and the two DV5 units at Wilmington Hospital. This distribution ensures that patients throughout the system have access to robotic surgery without geographic barriers.

“We are constantly assessing and adding technology as needed to keep our access to care as easy as possible for all patients within our system,” Dr. Santoro said.

ChristianaCare’s robotic surgery program stays at the forefront of innovation by actively evaluating new technologies and techniques, ensuring patients access to the latest surgical advances.

“This is a field that’s constantly evolving. We are always evaluating new technology. There are a lot of new companies that are developing robotic technology that will become more mainstream and utilized within healthcare systems very soon,” Dr. Santoro said. “ChristianaCare is definitely on the forefront of evaluating those systems for potential integration into our program.”

Through continued investment in technology, ongoing expansion of capabilities and commitment to surgical excellence, ChristianaCare’s robotic surgery program sets the standard for minimally invasive surgical care in the region, providing patients with the best possible outcomes through the most advanced surgical techniques available.

“ChristianaCare, as a healthcare system, is very much about expanding access for our patients,” Dr. Santoro said. “Just as we expand our capabilities, our specialists and our surgeons.”

 

References

  1. Cureus. 2024;16(2):e54433.
  2. J Gastrointest Surg. 2023;27(10):2057-2067.

In the field of surgical oncology, innovative techniques are transforming surgeries so patients spend less time in the hospital, recover faster and experience improved outcomes on their cancer journeys. At ChristianaCare, the surgical oncology team consists of four specialists: Leon Kushnir, M.D.; David Christopher Palange, D.O.; Arvind Sabesan, M.D.; and Brendan Hagerty, M.D. Together, they provide care for individuals with a broad range of conditions.

In general, a large portion of the practice focuses on upper GI and hepatobiliary cancers, pancreas cancer, liver cancer, stomach and small bowel cancers, and peritoneal surface cancer. In addition, Dr. Kushnir, an endocrine surgeon, specializes in thyroid, parathyroid and adrenal surgery. Dr. Palange focuses on rectal surgery—for both benign and malignant disease. As board-certified surgical oncologists, Drs. Sabesan and Hagerty treat a range of malignancies, including melanoma, sarcoma and other skin or soft tissue cancers.

Over the past year, the team focused on expanding the scope of their robotic surgery program so more patients can be treated with cutting-edge, minimally invasive techniques.

“We are working towards making our center the go-to place for minimally invasive pancreas, liver and bowel resection surgery,” Dr. Hagerty said. “This has not been done at ChristianaCare in the past, and—with few exceptions—isn’t being done elsewhere in the region.”

Within the next few months, the team will begin to offer a robotic-assisted Whipple procedure—also known as robotic-assisted pancreaticoduodenectomy—that can benefit those with complex cancers of the pancreas, duodenum and bile duct by reducing recovery time, decreasing pain and providing better outcomes than open surgery.

While it is associated with a longer operative time, robotic pancreaticoduodenectomy has been shown to generally correlate with high patient satisfaction scores and may result in better rates of survival at one year, three years and five years after surgery when compared with traditional open pancreaticoduodenectomy.1

“The ultimate goal with this program is not just to get patients out of the hospital and recovered faster, but to positively affect their overall outcomes,” Dr. Hagerty said. ““We believe this approach may mitigate post-operative complications and improve recovery which has been shown to improve cancer-related outcomes.”

For melanoma patients, Dr. Hagerty and his colleagues promote a cutting-edge technique called targeted axillary dissection, which potentially eliminates the need for more complex surgeries among those with clinical stage III disease.

“In the past, patients would have their melanoma resected and have the entire involved nodal basin resected as well—what’s called a lymphadenectomy,” Dr. Hagerty said. “More recently, we’re taking an approach where we give patients immunotherapy up front before surgery, have their nodes shrink down, and remove only the diseased nodes. We then check them for response, and tailor their approach based upon the degree of response seen in the lymph node.”

This personalized approach can essentially eliminate the need for larger surgery, decreasing morbidity and resulting in faster recovery times.

“The trials that have explored this approach have noted incredible results with excellent long-term outcomes, which were never seen in the melanoma space before,” Dr. Hagerty said.

In offering these and other innovative techniques for cancer patients, the ChristianaCare’s surgical oncology team is investing in cutting-edge care today with the goal of extending the health of patients well into the future.

“We want to benefit our patients not just in the short term, but in the long term as well,” Dr. Hagerty noted.

 

Reference

  1. Ann Gastroenterol Surg. 2021;5(5):589-596.

The ChristianaCare Oral and Maxillofacial Surgery & Hospital Dentistry department continues to expand its capabilities in both routine procedures and complex tertiary care, serving as a regional hub for comprehensive maxillofacial treatment.

The experts in the department integrate dental, medical, and surgical expertise into a single, highly specialized discipline.

“Oral and maxillofacial surgery (OMFS) is a specialty that bridges medicine, dentistry and surgery all together,” said Daniel Meara, M.D., D.M.D., the chair of ChristianaCare’s Department of Oral and Maxillofacial Surgery & Hospital Dentistry. “Our gamut is everything from wisdom teeth removal in the office setting to complex procedures like corrective jaw surgery and facial trauma reconstruction.”

The team manages a diverse caseload, from outpatient dental extractions to hospital-based interventions for facial trauma. As a Level I trauma center, ChristianaCare relies on the oral and maxillofacial surgery team to address facial injuries year-round. Their role has only grown in complexity with the addition of surgeons trained in oncology and reconstructive techniques, including microvascular free tissue transfer.

One of the department’s most distinctive offerings is total joint replacement of the temporomandibular joint (TMJ), a highly specialized procedure offered by only a few centers.

“Much like you would get a hip or knee replacement, we do the same thing for the TMJ,” Dr. Meara said.

Currently, there are only two FDA-approved prostheses for the procedure: A stock option and a custom-designed joint. The ChristianaCare team primarily uses the custom version, which is engineered to the patient’s unique anatomy.

“What we’re custom designing is patient-specific for their total joint replacement,” Dr. Meara said. “This is ideal for patients who have failed nonsurgical and often other surgical options.”

The team is also using computer-generated, virtual surgical plans in order to better illustrate and explain complicated procedures to patients.

Beyond surgical innovation, the department is playing a growing role in managing oral cancer, a condition with increasing incidence, due to human papillomavirus-related cases in younger populations, among other factors.

“There are approximately 50,000 cases in the U.S. each year, but oral cancer doesn’t get the same attention as other cancers,” Dr. Meara noted. “We’re working closely with the Helen F. Graham Cancer Center and our ENT [ear, nose and throat] colleagues to provide multidisciplinary, comprehensive care.”

This collaboration spans not only tumor resection but also complex reconstructive challenges, he added.

“It’s not just about removing the cancer,” Dr. Meara said. “It’s about how we rebuild the face and restore function afterward. This is a really important discussion for patients in Delaware.”

“ChristianaCare’s head and neck team, comprised of ENT, plastic surgery, and OMFS is able to offer head and neck cancer surgery and reconstruction, including free flaps for large facial defects,” Dr. Meara said. “You’d have to go to Philadelphia or Baltimore to find similar work being done at this scale in the region.” 

This summer, a new fellowship-trained surgeon will join the team, further bolstering ChristianaCare’s capabilities in maxillofacial oncology.

As the field of oral and maxillofacial surgery continues to evolve, ChristianaCare's team is committed to remaining at the forefront by integrating innovation, academic rigor and compassionate care. With an eye on expanding access and refining surgical techniques, the OMFS team is shaping a model for regional excellence in a truly hybrid specialty.

For patients with end-stage kidney disease, dialysis represents survival but not necessarily life. Kidney transplantation of any type offers a dramatically different outcome, significantly extending life expectancy and improving the quality of that life. The best outcomes of all are seen when a kidney is provided by a living donor. At ChristianaCare, the Living Donor Kidney Transplant Program gives people the opportunity to gift this lifesaving intervention to a patient in need.

“On hemodialysis, patients are typically sitting in a hemodialysis center three days a week for probably four hours each visit. They have two large needles placed in their arm, and they’re stuck there with this machine that cleans their blood. Without that dialysis, their life expectancy would be measured in days to weeks,” explained Jason Rolls, M.D., Surgical Director of the Kidney Transplant Program at ChristianaCare. “Some patients choose peritoneal dialysis, rather than hemodialysis. They have a tube placed in their abdomen, and they dialyze by passing large amounts of fluid through it, letting it sit inside them for hours before it is drained out. Either method of dialysis is a horrible way to live, for most people.”

“Statistically speaking, if you put a hundred adults, comprising a range of ages and medical conditions, on dialysis today, half of them will no longer be with us in just under four to four and a quarter years,” he added. “Transplanting people at any age from childhood into their 60s statistically more than doubles life expectancy. Even well-selected patients in their late 70s can enjoy twice as many remaining years.”

Most kidney donations come from deceased organ donors. While these kidneys provide excellent outcomes, waitlists can be long, and patients may get sicker while they wait for their opportunity for transplantation. Living donor recipients typically receive their transplant within months rather than years.

Living donor kidneys, coming from carefully screened healthy individuals during scheduled procedures, statistically last twice as long as deceased donor kidneys. This extended graft survival means that recipients receiving proper medical care can expect decades of function from a living donor kidney.

Kidney donation is a significant personal commitment, but its impact on a recipient cannot be overstated. ChristianaCare’s program addresses common barriers to living donation to ensure that almost every willing and able donor candidate will go on toto help a patient in need. Even when blood type or tissue compatibility issues exist, the program can arrange for paired kidney exchanges with other transplant centers by virtue of its participation in the National Kidney Registry, allowing these barriers to be overcome.

“Being part of the largest and most productive paired exchange organization in the country means that things like ABO blood group compatibility or immunologic incompatibility between an otherwise willing and medically appropriate donor and recipient pair should never be a barrier for us,” Dr. Rolls explained.

As people consider giving a gift of one of their kidneys to another, it is important for them to know the following:

  • Statistically, someone who has donated a kidney ends up living longer than the general population. (They do not live longer because they donated their kidney, but because they are healthier than the general population to begin with.)
  • Statistically, someone who has donated a kidney is not at increased risk for developing end-stage renal disease than does the general population.
  • From the moment the potential donor candidate picks up the phone for the first time to call their transplant center and inquire about the process to the moment they are put to sleep for the donation surgery, they can change their mind and opt out. They maintain control over their own destiny as far as the living organ donation process is concerned, and their decision is final.
  • Undergoing evaluation to be a living donor is likely to be the most diagnostic testing these patients have ever received (at no cost). Imaging, blood testing, heart and kidney function testing, evaluations by physicians, and other assessments are all free to the donor candidate, even if they later opt out.
  • Medical information revealed during the living donor candidate’s evaluation process remains private, between the candidate, their physicians and their medical chart. Nothing concerning their medical information can be revealed to anyone else, including their intended recipient, without their express permission.

ChristianaCare’s kidney transplant program has experienced significant growth, increasing from 15 transplants in 2020 to 54 in fiscal year 2025. Despite the program’s growth ChristianaCare’s Transplant Team has maintained its commitment to the personalized care that it has always embraced.

“Every patient is an individual, with their own journey. We are here to ensure that journey is as successful as possible for them,” Dr. Rolls said.

Looking ahead, ChristianaCare continues to embrace innovations that expand transplant opportunities.

“Surgeons like ours are working harder and more thoughtfully to use deceased-donor organ opportunities that we are offered, many of which we would not have seriously considered five to 10 years ago, and we have found that they do quite well. Our community continually pushes this envelope in the interest of allowing our patients to live longer, healthier lives, filled with hope,” Dr. Rolls said. “However, living donation remains the best possible current routinely available option for anybody with end-stage renal disease. People willing to give someone else a kidney remain all too rare and precious. We look forward to further efforts at increasing public awareness and to the day when they are less rare.”

Spring 2025 Issue

Adults who have moderate to severe obstructive sleep apnea (OSA) may benefit from a surgical option known as maxillomandibular advancement (MMA). ChristianaCare is currently one of the few health systems in the region performing this surgery

The American Academy of Sleep Medicine estimates that at least 25 million people in the United States have OSA. The condition occurs when muscles and soft tissue in a person’s throat repeatedly relax and collapse during sleep, blocking their airway and causing recurrent waking to restore breathing, which can seriously disrupt sleep and lead to reduced blood oxygen levels, according to Daniel J. Meara, MD, DMD, FACS, the chair of ChristianaCare’s Department of Oral and Maxillofacial Surgery and Hospital Dentistry.

Some of the major risk factors for OSA include obesity, smoking, alcohol consumption, asthma and chronic nasal congestion.

Men are several times more likely to have OSA than premenopausal women; however, the prevalence among women increases following menopause, Dr. Meara said. While the condition may affect people at any stage of life, it’s most common in middle-aged and older adults.

Symptoms of OSA include loud snoring, difficulty sleeping, pauses in breathing while asleep, frequently waking to urinate, morning dry mouth, headaches, daytime sleepiness, impaired concentration and impotence. Left untreated, Dr. Meara warned that the condition can cause a host of health concerns.

“People with OSA are at higher risk for hypertension and cardiovascular disorders, such as irregular heartbeat, heart attack and stroke,” Dr. Meara said. “They’re also more likely to develop metabolic syndrome, diabetes, liver disease, cognitive impairment, depression and anxiety. Further, when OSA is poorly controlled, there is significant negative impact on quality of life. That’s why it’s so vitally important that they receive treatment.”

For adults, making lifestyle changes or using oral appliances may be sufficient for managing the condition in its mild form, but those with moderate to severe disease typically require continuous positive airway pressure (CPAP) therapy, which is the gold-standard for treatment. However, compliance with CPAP can be low, necessitating alternative treatments, primarily surgery. Surgical options include uvulopalatopharyngoplasty (UP3), hypoglossal nerve stimulation (HNS; which uses an implanted electronic device to open a patient’s airway during sleep) and maxillomandibular advancement jaw surgery, according to Dr. Meara.

However, when UP3 and HNS techniques either aren’t appropriate or have failed to resolve the problem, MMA has proved to be a strong alternative.

“The surgery is performed on patients in a hospital operating room under general anesthesia,” Dr. Meara said. “MMA involves making incisions in the upper and lower jaw bones and moving them forward. This opens the upper airway to enhance airflow and improve breathing during sleep. The procedure generally lasts several hours and requires a hospital stay.”

Possible postoperative side effects include pain, bleeding, swelling, nasal congestion, teeth bite changes, weight loss, and temporary numbness in the lips, mouth or face. There also is a minor risk for complications, including infection and damage to teeth.

In most cases, patients are able to return to their daily activities and work in approximately four to six weeks.

“Research has found that MMA is highly effective, with a high success rate,” Dr. Meara noted. “For patients, the biggest benefit is that the procedure is a more permanent solution to OSA, whereas many of the other treatments require the nightly wearing of sometimes uncomfortable equipment that have their own side effects.”

Patients seeking state-of-the-art eye care in Delaware can now receive virtually all types of ophthalmic surgery close to home, as ChristianaCare has added three new fellowship-trained physicians to the staff within the past two years.

Glaucoma specialist Tomilade Adepoju, MD, who completed her ophthalmology residency at Nassau University Medical Center, in East Meadow, N.Y., and her glaucoma fellowship at Boston University Eye Associates, came on board in September 2022. Medical retina and uveitis specialist Benjamin Christopher Chaon, MD, the medical director of the Wilmington Eye Clinic and an associate professor of ophthalmology at Temple University, in Philadelphia, joined the staff in the summer of 2023. And, most recently, ChristianaCare has recruited the first neuro-ophthalmologist in the state of Delaware, Muhammad Asad Fraz, MD, who completed his neurology residency at Henry Ford Hospital, in Detroit, and a fellowship in neuro-ophthalmology at the University of Pennsylvania, in Philadelphia.

“Between the three of us, we are able to cover just about every area of ophthalmology, which means that we no longer have to refer patients with very complex eye conditions to practices in Philadelphia or Baltimore,” Dr. Adepoju said. “Our program is also affiliated with the Temple University ophthalmology residency, an exceptional training program, so we have residents who operate with us and learn from us in the clinic and operating room.”

As the population continues to age, the demand for cataract surgery is growing dramatically.

“We perform the simplest to the most complex surgeries,” she said. “Because we offer these procedures in the hospital setting, where we can manage patients holistically in collaboration with our colleagues in rheumatology, endocrinology and critical care, we are particularly well suited to care for the most challenging and difficult cases, such as people with long-standing diabetes and many other comorbidities. The majority of our patients are already somehow being cared for within the ChristianaCare system, so having the whole care team under the same umbrella is very helpful.”

Surgeries are performed at ChristianaCare’s Wilmington Hospital, which is also the primary location for the ophthalmology practice. Here, patients have access to laser procedures, minimally invasive surgeries, and traditional surgical options depending on their clinical situation.

“In this facility, we have a new Heidelberg Spectralis optical coherence tomography machine, which provides noninvasive imaging of the retina for the diagnosis of retinal disease and allows us to assess the optic nerve for patients with glaucoma,” Dr. Adepoju noted. “We also have two lasers for the treatment of glaucoma that may not yet be at the point of needing traditional incisional surgery, as well as a micropulse photocoagulation laser to treat more severe glaucoma in the OR setting. All of our equipment is state of the art.”

Within the next one to two years, the group also hopes to expand to a second location offering medical and surgical ophthalmic services at Christiana Hospital in Newark. Demand is high: Both Drs. Adepoju and Chaon are booked into early 2025 and Dr. Fraz through March 2025. However, the practice has dramatically increased the number of patients it is able to see, conducting between 300 and 400 diabetic screenings per month and performing between 10 and 14 surgeries monthly for each surgeon. The team works closely with referring providers to ensure that patients who need urgent ophthalmic care can be evaluated at ChristianaCare in a timely fashion.

“We also plan to expand and add one more specialist to the ophthalmology team within the coming year,” Dr. Adepoju said. “We are growing very quickly because there is such a need in this community for ophthalmic surgical care.”

When patients undergo imaging studies such as MRIs, CT scans and ultrasounds to screen for a variety of cancerous or noncancerous conditions, sometimes the scan reveals an unexpected finding: a nodule on the thyroid.

“Someone may have a traumatic injury and get a CT scan of their entire body, or they are experiencing neck pain or a muscle sprain or an issue with their cervical spine, and they get an MRI,” explained Leon Kushnir, MD, FACS, a fellowship-trained endocrine surgeon who joined the staff at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute in the summer of 2024 after several years as the program director of the general surgery residency program at Inspira Health Network in southern New Jersey. He joined an experienced team that includes Arvind Sabesan, MD, FACS, a surgical oncologist with a special interest in endocrine surgery, and Alison Segal, a physician assistant with more than 25 years of surgical expertise.

“During that imaging, an incidental thyroid nodule is seen, which suddenly becomes a significant concern for the patient,” Dr. Kushnir continued. “They don’t really know how to react. Could it be cancerous?”

Many patients experience a lot of anxiety after they are told about this finding and want to be seen by an expert as soon as possible. Although the vast majority (up to 90%) of thyroid nodules are benign, they still require proper management—and patient education and consultation.

With Dr. Kushnir’s assistance, ChristianaCare has launched a new clinical pathway for the management of thyroid nodules. This process removes the burden of these findings off of the referring physician and immediately puts the case in the hands of an expert.

“When an incidental thyroid nodule is identified on imaging, it is flagged on the radiology report and the ordering physician is immediately given the information to refer the patient to myself or my partner, Dr. Sabesan,” Dr. Kushnir explained. “We will take care of everything from there.”

Within the past 10 years, genetic analysis has significantly improved the ability of surgeons, like Dr. Kushnir, and the pathologists he works with to accurately diagnose these nodules.

“When I first started my training, biopsy results were not very specific. We often performed extensive diagnostic surgeries on nodules that turned out to be benign,” he said. “Today, it’s relatively unusual for us to be doing a surgery when we don’t know definitively whether or not it is cancer.”

Dr. Kushnir envisions the thyroid nodule clinical pathway as a seamless process for the patient and the referring provider.

“Apple is very successful and famous because they make it very easy to use their products,” he noted. “We need to also make it very easy for our colleagues and patients to get expert care in a timely and easy fashion. One or two clicks will enable our referring providers to contact us, and we will get the patient in our door for a workup and in-office biopsy as soon as possible.”

Most of the time, incidental thyroid nodules turn out to be benign; Dr. Kushnir estimated that they are cancerous only between 5% and 10% of the time. However, time is still of the essence with these findings; “a lump on the thyroid” often still represents an emotional emergency to the patient.

“In my experience, whenever a patient sees that sort of incidental finding, they get very scared,” Dr. Kushnir said. “That’s especially acute when somebody has a personal or family history of cancer.”

Unfortunately, in the past, it could often take several months between identifying an incidental thyroid nodule on a scan and finally ruling cancer in or out.

“We’re going to change that,” Dr. Kushnir noted. “We want to make that transition from identifying a nodule, to counseling and biopsy, to having an answer as easy and quick as possible. Our goal is to have the patient seen in our office within one to two weeks after the initial diagnosis. At this visit, they will have a full consultation with a biopsy of the nodule if necessary, and results available the following week.”

ChristianaCare’s Center for Breast Reconstruction is the only such program in Delaware offering microsurgery fellowship−trained plastic surgeons. This enables the program, which has three microsurgery-trained surgeons—two of whom are women—to offer the full range of breast reconstruction modalities, including flap reconstructive surgeries in which microsurgeons use a patient’s own body tissue to reconstruct the breast. Occasionally, patients request an all-female team, and ChristianaCare is able to provide that.

In flap surgery, the most common area where surgeons find tissue to use is the lower abdomen. If surgeons can’t use abdominal tissue, perhaps because the woman is too thin or has had surgery on the abdomen before, they may be able to use tissue from the lower back, buttock or upper thigh. Using a person’s own tissue to reconstruct a breast has several benefits. First, it allows for a more natural look.

“The biggest advantage is that the reconstructed breast is made up of your own body tissue and replaces like for like,” said Stephanie Caterson, MD, the director of the Center for Breast Reconstruction at ChristianaCare. “With flap reconstruction after a mastectomy, the breast is replaced with skin and fat from the lower abdomen, which feels very natural for the patient. It also ‘ages’ much like a natural breast. If a patient gains or loses weight, the flap tissue fluctuates with the body over time, resulting in long-lasting symmetry.”

The second benefit of flap surgery is that it doesn’t use implants that require a lifetime of annual visits for imaging and assessment.

“Implant reconstruction is a great option for many people, but we need to remember that they are manmade products that will undergo normal wear and tear,” Dr. Caterson said. “If the outer lining of an implant breaks, it should be replaced. We recommend annual clinic visits to monitor the implants, and after five years, we start performing implant imaging to ensure the implant is intact. With implants, there is the lifetime risk of potentially having multiple surgical interventions. There is not a lot of maintenance surgery that goes with flap surgeries.”

Third, flap surgery is a better option for patients who have undergone, or are going to undergo, radiation for their breast cancer treatment.

“Implants and radiation basically don’t get along very well,” Dr. Caterson noted. “With radiation, sometimes scar tissue can build up around the implant, or the skin around the implant can really tighten up and change the shape, look and feel of the implant. We often recommend flap reconstruction after radiation to bring healthy tissue into the radiated field.”

Dr. Caterson pointed out that ChristianaCare offers the full range of breast reconstruction options, from implant reconstruction all the way through the complex tissue reconstructions. She said flap surgery isn’t for everyone, as it involves longer procedure and recovery times than implant surgery.

The most common type of flap surgery is the deep inferior epigastric perforator (DIEP) flap, which uses the lower abdominal skin and fat to reconstruct the breast. DIEP flap surgeries can take between four to eight hours for one breast or eight to 12 hours for two breasts. A patient must be otherwise healthy to be considered a good candidate for this long procedure.

“Basic implant reconstruction may be one or two additional hours if you are doing it at the same time as the mastectomy,” Dr. Caterson said. While an implant surgery involves one night in the hospital and then usually a three-week recovery, DIEP involves three to four days in the hospital and six to eight weeks recovery time, she added.

“What sets our group apart is that each of our fellowship-trained microsurgeons offers the full range of breast reconstruction options, creating personalized surgical plans tailored to each patient’s medical needs and personal preferences.” Dr. Caterson noted.

Another unique part of the breast reconstruction care practice at ChristianaCare is the team approach with surgeons, physician assistants, schedulers, office staff and medical assistants all working together cohesively.

“I can’t tell you how proud I feel when I’m sitting in my office and I overhear a patient stop at our medical assistant’s desk on the way out to thank them for being so kind and supportive, or helping them with their drain, or whatever it might be,” Dr. Caterson recounted. “A breast cancer diagnosis is often the most challenging thing a woman has gone through in their life, and we would like our office to be a support system for them. We try to be the silver lining of what they have gone through

Robotic technology allows colorectal surgeons at ChristianaCare to perform complex abdominal surgeries to treat patients and save lives. Indeed, the techniques enabled by robotics can improve patient outcomes and reduce costs of care.  

Caitlyn M. Costanzo, MD, is a distinguished general and colorectal surgeon at ChristianaCare. She performs a wide variety of surgical procedures for the treatment of benign and malignant colorectal pathology. This includes segmental small and large bowel resections, low anterior resections (LAR), abdominoperineal resections, and complex reconstructions to restore bowel continuity. In the past, Dr. Costanzo primarily used laparoscopy for her procedures. Now, she has successfully incorporated the da Vinci Xi (Intuitive Surgical) surgical technology into her surgical practice.

The da Vinci Xi is a robotic surgical system that includes a patient cart that consists of four surgical arms and a surgeon console, where Dr. Costanzo sits and controls the robotic arms. The enhanced technology enables surgeons to visualize human anatomy in high-definition 3D. The surgical arms have multiple degrees of freedom and have built-in tremor-filtration technology.  With the assistance of Firefly fluorescence imaging, Dr. Costanzo can identify important anatomy and ensure that the blood supply to the intestine is adequate for healing.

“Robotic surgical technology can improve patient outcomes by reducing intestinal manipulation,” she explained. “The entire surgery can be performed within the abdominal cavity, which allows patients to recover bowel function sooner.”  

What Dr. Costanzo is referring to is an intracorporeal anastomosis, or ICA. Once a segment of intestine is removed, the restoration of bowel continuity is performed in the abdomen, so that there is no exposure of bowel to the outside environment. The reduction of external intestinal manipulation allows patients to have a quicker return of bowel function and thereby a shorter length of stay. Dr. Costanzo’s robotic surgery patients leave, on average, 1.5 days sooner than laparoscopic patients. 

The robotic platform is especially helpful in certain patient populations. When the human anatomy makes it difficult to see or feel, the robotic technology enables surgeons to work in confined spaces, for example deep in the pelvis. Additionally, the ability to restore intestinal continuity while inside the abdomen means that the challenges of being able to deliver the intestine outside of the body are obsolete.

“Surgical technology is always advancing, yet I believe that robotics has proven to be the biggest advancement during my generation of surgery,” said Dr. Costanzo.

She is excited to be able to offer this modality to her patients.  

With all the hype surrounding the new weight-loss medications, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), clinicians may be getting questions from patients about treating morbid obesity via pharmacotherapy versus bariatric surgery. So, what can—and should—clinicians tell these patients?

“Medications are for short-term weight loss, are more expensive, have less of an effect and they provide less sustainability,” said Mingwei Ni, MD, a bariatric surgeon at ChristianaCare. “Bariatric surgery is obviously more invasive, but it is more effective in the treatment of morbid obesity and its associated diseases. Surgery works much faster than medication and will maintain weight loss for a lifetime. Patients who undergo bariatric surgery will lose 60% to 70% of their excess body weight versus 20% to 30% with medication. That is a huge difference.”

Roughly one-third of Americans are obese, and more than half of these people are considered morbidly obese (body mass index, ≥40 kg/m2). Morbid obesity is one of the main causes of many chronic and life-threatening diseases, including hypertension, type 2 diabetes, stroke, coronary artery disease, heart failure, kidney failure and peripheral vascular disease. Morbid obesity is also a very strong risk factor for numerous types of cancer, including breast and colon cancer.

Weight-loss medications have been on the market for 30 years, with many of the older drugs working by, for example, suppressing the absorption of fat or by increasing metabolism. The GLP-1 RAs, currently injectable medications, work by making the stomach wall move less, thus keeping food in the stomach longer. The result is that people feel full very quickly and are less hungry.

The two most common options for bariatric surgery are sleeve gastrectomy and gastric bypass. While bariatric surgery can treat the medical comorbidities that are associated with morbid obesity, the GLP-1 RAs are only able to treat diabetes—and not as well as bariatric surgery.

“Weight-loss surgery will help you lose weight in order to treat comorbidities such as diabetes, hypertension and sleep apnea, and will prevent heart attack and stroke,” Dr. Ni said. “The newer weight-loss medications don’t really treat these medical comorbidities, and the medications can cause GI symptoms that people can’t tolerate, such as stomach pain, nausea, vomiting, diarrhea and heartburn.”

Surgery also has a much higher chance of bringing patients’ BMI back to a healthy level. Of note, the weight loss is a more sustainable option compared with weight-loss medications. For example, with the GLP-1 RAs, when patients stop using them, they usually gain the weight back.

“Bariatric surgery will hopefully last a lifetime, especially if the patient is willing to change their lifestyle and work with a dietitian,” Dr. Ni said.

The new weight-loss medications are also very expensive at roughly $1,000 per month per patient, he added.

“The cost of surgery is much lower and insurance covers it,” Dr. Ni said. “The copay out of pocket depends on insurance, but Medicaid and Medicare almost cover 100%.”

That said, sometimes both bariatric surgery and weight-loss medications are used concomitantly.

“Weight-loss treatment can be a combination of the medication, surgery and lifestyle changes such as diet and exercise,” Dr. Ni noted. “It’s a really multidisciplinary approach to treat this disease.”

At ChristianaCare, a team approach is used to treat a patient with morbid obesity.

“It’s very important to work with a well-trained experienced team of dietitians, psychologists, a physician who will optimize the patient for surgery, bariatric surgeons, a nurse practitioner who can follow the patient long term and a support group for patients to attend before and after surgery,” Dr. Ni explained.

For example, ChristianaCare offers free online educational seminars for patients given by two bariatric surgeons. They also offer a 174-page healthy recipe book on the ChristianaCare bariatric website, which is free for download.

“In general, weight-loss surgery is as safe as gallbladder surgery or knee replacement surgery. It’s a small incision to do the surgery,” Dr. Ni said. “We offer outpatient sleeve gastrectomy for patients with suitable indications.”

Dr. Ni added that all patients undergoing bariatric surgery go home without the need for narcotics. “Pain is usually controlled by non-narcotic medications such as [acetaminophen] and a muscle relaxant,” he said. “Bariatric surgery is a very good and a very safe option.”

Summer 2024 Issue

Bariatric surgeons at ChristianaCare are using weight-loss procedures as a tool for patients with obesity to foster improved health metrics across a number of disease states.

Patients undergoing Roux-en-Y gastric bypass and sleeve gastrectomy have not only lost weight but have also seen positive improvements in comorbid type 2 diabetes, hypertension, and cardiovascular and kidney disease, as well as reduced levels of low-density lipoprotein (“bad cholesterol”) and hemoglobin A1c. Many of these patients have struggled maintaining a healthy weight despite other interventions such as exercise programs, dietary changes and even medications, according to Elizabeth McCarthy, MD, a minimally invasive bariatric surgeon at ChristianaCare.

“For a lot of patients, bariatric surgery is the last stop in their weight-loss journey,” Dr. McCarthy said. “They have been living with obesity for some time and are dealing with a number of health complications as a result. Some have even been told they will die unless they lose weight and have the surgery. Our goal at ChristianaCare is to guide these patients and their families through surgery, and we provide them with support before, during and after their procedures to help them get the best results.”

Because of type 2 diabetes, cardiovascular disease, kidney disease and hypertension, among other potential health problems, many patients undergoing bariatric procedures—most of which involve sleeve gastrectomy at ChristianaCare—are on multiple medications before surgery. However, after surgery, most patients can expect to take medications at lower doses or come off them altogether, according to Dr. McCarthy.

However, management of these patients doesn’t stop immediately after surgery. In fact, patients are monitored postoperatively for an indefinite period to ensure they are maintaining a healthy weight and still doing well with any comorbid conditions, she said.

“If they are struggling with weight, even postoperatively, we provide them with the education and resources they need to get back on track,” she added.

This education is actually a continuation of the patient instruction that begins preoperatively. Before surgery, patients typically meet with a nutritionist to review their diet and a psychiatrist to assess for underlying disordered eating or mental health conditions that may contribute to weight gain or hinder weight loss.

In addition, ChristianaCare has developed an online seminar that patients are encouraged to view before their initial surgical consultation. It reviews what to expect in the lead-up to surgery, during the procedure and after it. Primary care physicians and practitioners should encourage patients who are interested to sign up and learn more about bariatric surgery, Dr. McCarthy said.

On top of that, bariatric surgery patients at ChristianaCare are required to take several virtual classes, via Microsoft Teams, delivered by the Weight Management team. These classes advise patients on diet and exercise and, in general, “how to stay committed and engaged in their health journey” after surgery, Dr. McCarthy explained. “There’s a lot of work that’s involved getting to surgery, and it can take up to a year.”

That said, the goal is not to make the process more difficult; rather, it’s designed to ensure success. Currently, bariatric surgery is recommended for adults with a body mass index more than 35 kg/m2 and a medical comorbidity such as type 2 diabetes, hypertension and sleep apnea, as well for those with a BMI greater than 40 kg/m2, as they are at increased risk for these and other comorbidities, including infertility and polycystic ovary syndrome. However, less than 1% of patients who meet the criteria for surgery nationally ultimately are referred for these procedures.

“A lot of that is due to the stigma surrounding obesity,” Dr. McCarthy explained. “That’s why it’s so important for us to create an environment where patients feel supported.”

Some of that support is provided by the patients themselves. The bariatric surgery team at ChristianaCare oversees a monthly online support group led by patients who have had the procedure within the system and includes topics from the team’s dietitians, surgeons and other providers directly involved in the bariatric patient’s care.

“Patients share their experiences and encourage each other to maintain a healthy lifestyle and get the most from their surgery,” Dr. McCarthy said. “Surgery is a great tool to get you where you want to go, but it’s just that: a tool. Patients will need to keep working to be successful, and being successful requires support. That’s why we strive to have an excellent supportive practice with a multidisciplinary team that works with all of our patients preoperatively and postoperatively. That separates ChristianaCare from a lot of surgical practices.”

When a patient presents with complicated diverticulitis—with perforation, abscess, obstruction and/or fistula—to ChristianaCare, admission to the hospital is usually required.

Indeed, if the patient has peritonitis, surgical removal of a portion of the colon is required. Traditionally, this would entail removal of the sigmoid colon and creation of a colostomy. More recently, however, research has shown that it is safe and effective to remove the sigmoid colon and divert stool via an ileostomy, according to David C. Palange, DO, a colon and rectal surgeon at ChristianaCare’s Helen F. Graham Cancer Center and Research Institute. At ChristianaCare, this procedure is performed using state-of-the-art tools and approaches.

“If you become my patient, particularly for elective procedures, you’re getting a robotic or laparoscopic surgery with all incisions the size of my thumbnail,” Dr. Palange said. “Through minimally invasive techniques for robotic-assisted or laparoscopic surgery, you definitely decrease the chances of wound infection and pain.”

In fact, with the use of the robot, “the surgeon can suture and staple and perform other tasks” more quickly and accurately, reducing the risk for postoperative infection, time under anesthesia and other potential complications, he added.

A colostomy reversal remains a challenging procedure due to residual scar tissue. In contrast, ileostomy reversal is relatively easy for the surgeon to perform. As a result, with ileostomy a patient can anticipate a fuller recovery, restoring normal bowel movements, according to Dr. Palange.

Patients undergoing colostomy have about a 50% chance for reversal, but the percentage with ileostomy is much higher, he said.

Recovery times from surgery for complicated diverticulitis vary, Dr. Palange added. If a minimally invasive surgery is performed using enhanced recovery after surgery protocols, a patient typically stays in the hospital two to five days, with recovery expected to take two weeks and complete healing taking place within six weeks. With open procedures, hospital stays and recovery and healing times are much longer, Dr. Palange said.

Generally, about one in four patients with diverticulitis develop complicated disease. For the far more common uncomplicated, non-severe form of the condition, which involves localized inflammation of the diverticulum, a more conservative treatment approach is used.

Traditionally, uncomplicated diverticulitis has been managed with antibiotics and a liquid diet, and most patients recover at home without hospitalization. However, at ChristianaCare, Dr. Palange and his colleagues adhere to updated guidelines from the American Gastroenterological Association, which recommend “selective, rather than routine, antibiotic use in immunocompetent patients with mild disease.”

While antibiotics have long been the first-line therapy for acute uncomplicated diverticulitis, recent evidence suggests there is no benefit from their use in immunocompetent patients with mild acute uncomplicated diverticulitis, according to Dr. Palange.

“Historically, the use of antibiotics for acute cases has been in response to what was believed to be an immediate infection, but it is now understood that it’s the inflammation and not the infection that causes the symptoms,” he said. “This newer approach of selective use of antibiotics has not yet been widely adopted, but we’re using it here to prevent overuse of antibiotics, which can later lead to resistance and unnecessary side effects.”

Dr. Palange added: “Colonic diverticulitis remains a painful, unpredictable gastrointestinal disease that can lead to serious complications, chronic symptoms and poor quality of life. At ChristianaCare, we strive to use the latest, evidence-based approaches to give our diverticulitis patients the best possible outcomes.”

Evolving screening techniques, coupled with minimallyinvasive surgical solutions, are allowing physicians at ChristianaCare to look beyond gallstones in caring for patients with abdominal pain.

“We used to always think there was only one issue with the gallbladder—gallstones,” said Michael B. Goldberg MD, a minimally invasive surgeon practicing at ChristianaCare. “Now we know that it’s not actually only gallstones that give people gallbladder symptoms and upper right quadrant pain. There is much more to it.”

Patients experiencing this type of pain, which is often quite debilitating, may have biliary dyskinesia, a condition in which the gallbladder is not squeezing as hard or as fast as it should. Biliary dyskinesia can result in insufficient amounts of bile being ejected from the gallbladder into the small intestine.

Conversely, some patients may also have biliary hyperkinesia, when the gallbladder squeezes too fast and too hard, causing recurring biliary colic.

Both conditions can cause significant pain and discomfort. However, when testing indicates no presence of gallstones, patients’ pain would often go untreated.

“People who were suffering from right upper-quadrant abdominal pain and the inability to tolerate meals would get an ultrasound and it would look normal—with no gallstones—and we thought that was the end of the story,” Dr. Goldberg said.

Now, hepatobiliary iminodiacetic acid (HIDA) scans allow for far more detailed review of gallbladder function, enabling specialists to more properly identify the cause of their patients’ symptoms.

“The HIDA scan can show us exactly how the gallbladder is functioning, and allows for more investigation in order to help our patients who are experiencing gallbladder symptoms without gallstones,” Dr. Goldberg said.

If the gallbladder is determined to be functioning incorrectly and needs to be surgically removed, current techniques allow for far easier procedures with greatly reduced recovery times.

“We use the latest minimally invasive techniques including laparoscopic and robotic surgery with smaller incisions,” Dr. Goldberg said. “It used to be that people needed to stay in the hospital when they had gallbladder surgery. Now it is done on an outpatient basis.”

Most people are able to manage the discomfort of gastroesophageal reflux disease (GERD) with lifestyle changes and medications. However, patients who have failed medical management or who don’t want to be on proton pump inhibitors, due to potential side effects, are candidates for surgery, according to Anthony R. Tascone, MD, a bariatric and foregut surgeon at ChristianaCare.

Other patients should be considered candidates for a surgical intervention are those who have Barrett’s esophagus, esophagitis or stricture from changes in their esophagus from reflux, he said. For all surgery patients, Dr. Tascone and his colleagues are using state-of-the-art procedures to achieve optimal outcomes in GERD.

For decades, fundoplication has been the gold standard for GERD surgery. During the procedure, the surgeon takes the top part of the stomach and wraps it around the bottom of the esophagus, with the goal, essentially, of bolstering the lower esophageal sphincter (LES). The procedure can entail a partial or total (Nissen) wrap, depending on the severity of esophageal motility.

Today, these procedures are minimally invasive and many surgeons at ChristianaCare are performing GERD surgeries robotically. Following surgery, most patients see improvement in their symptoms and can either be taken off medications completely or continue them at lower doses. More than four in five patients undergoing these procedures will see complete resolution of symptoms, with no need for medication.

“There are pluses and minuses to each of these approaches while the surgical outcomes for both are excellent,” Dr. Tascone said. “An important benefit of fundoplication is that the patient’s native tissue is used.”

Another GERD procedure performed at ChristianaCare involves implantation of the LINX reflux management system (J&J Med Tech), a novel device composed of a ring of magnets designed to strengthen the LES. Following surgical insertion, the LINX device is in the “closed position most of the time” to keep acid in the stomach, according to Dr. Tascone.

“The LINX has the ability to open and close so that food and drink can pass through it and patients can burp or vomit, as needed, when air forms in the stomach,” he said. “That is harder to do following fundoplication.”

In general, outcomes following LINX implantation are similar to those for fundoplication, which research leads to improved symptom control and quality of life in 90% of patients.1 Still, a downside of LINX is that up to 40% of patients develop dysphasia during the few months following the procedure.2

Another recent addition to the surgical armamentarium for GERD at ChristianaCare is gastric bypass, particularly for patients with elevated body mass index. In addition to treating GERD, gastric bypass helps treat common comorbidities, including hypertension, type 2 diabetes, obstructive sleep apnea, and hyperlipidemia, by fostering weight loss.

“So, patients will get more bang for their buck when undergoing gastric bypass surgery,” Dr. Tascone said. “The outcomes for all of these procedures are very similar, though recovery is slightly different for each option. Laparoscopic surgery has a quicker recovery time and less pain than open surgery. The primary care doctor and the surgeon can work together to help decide which is best for the patient.”

 

References

  1. John M, Irvine T, Thompson SK, et al. Antireflux surgery in patients with gastroesophageal reflux but a negative 24-hour pH study—late outcomes. J Gastrointest Surg. 2024:S1091-255X(24)00449-9.
  2. Fadel MG, Tarazi M, Dave M, et al. Magnetic sphincter augmentation in the management of gastro-esophageal reflux disease: a systematic review and meta-analysis. Int J Surg. 2024 May 9.

At The Hernia Center at ChristianaCare, surgeons are using innovative technological approaches, paired with highly customized individual care plans, to provide cutting-edge treatment. The approach allows for low-risk procedures with faster recovery times, for patients with either minor or major surgical needs.

“Historically, patients have been a bit wary of hernia surgery for lots of different reasons,” said Peter M. Santoro, MD, the director of robotic surgery and medical director of The Hernia Center at ChristianaCare. “They may have heard from a friend or family member how painful it was, or how hard it was to recover from the procedure. Maybe they know people who had issues with mesh or other complications from their surgery.”

Much of this, according to Dr. Santoro, was due to the fact that hernia repair has often required open surgery necessitating large incisions. Too frequently, this meant that patients were faced with complicated procedures, long hospital stays and often painful, time-consuming recoveries.

However, over the past two decades, minimally invasive techniques have revolutionized many surgical specialties, hernia care included. As technology has rapidly advanced, developments in robotic surgery have allowed for previously unthinkable improvements in both surgical accuracy and patient recovery.

“From the smallest hernias to the most complex cases that require abdominal wall reconstruction, we’ve been able to move from big-incision operations to minimally invasive surgery,” Dr. Santoro said. "A huge part of that has been the advancement of robotic surgery, which has taken hernia treatment to a level that has never previously been seen, from a technical standpoint, as well as through patient satisfaction and recovery. It’s changed the way we take care of patients with hernias.”

The most recent advancement has been in the management of complex ventral hernias, which require abdominal wall reconstruction via transversus abdominis release (TAR) procedures.

“These TAR procedures traditionally could only be conducted as an open operation, and were reserved for the most complex ventral abdominal wall hernias,” Dr. Santoro said. “The postoperative course was typically very rocky, with significant complications on a fairly routine basis.”

Now, robotic abdominal wall reconstruction via the robotic TAR procedure has enabled surgeons to adopt novel techniques in order to vastly minimize the risks associated with these procedures.

“Robotic TAR has completely revolutionized the way we deal with complex abdominal wall hernias and abdominal wall reconstruction,” Dr. Santoro said. “It’s taken an operation that was associated with about a week-long hospital stay, with a high risk of perioperative complications, and reduced it to an overnight stay with very rare incidence of complications and a much easier recovery course for the patient.”

Currently, most patients undergoing hernia repair surgery—particularly when robotic techniques are used—can expect a same-day discharge from the hospital and a speedy return to normal activities.

“A minor subset of patients may require a one-night stay in the hospital, but the vast majority will be able to go home the same day,” Dr. Santoro said.

In addition, unlike with open procedures, postoperative pain following minimally invasive surgery can frequently be managed without the use of opioids or other narcotic medications. While heavy lifting and strenuous physical activity is typically limited for a four-week period, patients can expect to be up and about within hours of their procedure, a fact that strongly benefits the recovery process.

“I expect patients to be walking around, going up and down stairs, getting in and out of the car even the same day as the operation, and certainly by the next day,” Dr. Santoro said. “We don’t want patients to be sedentary after surgery.”

As the exact needs of patients depend upon multiple factors, Dr. Santoro and his colleagues put great effort into developing and communicating plans that are unique to each person.

“With hernia surgery, the surgical process is very patient-specific,” Dr. Santoro said. “It’s a highly tailored approach even compared with other types of medicine. Every patient that has a hernia is different, and we take a very individual approach for every patient. We provide comprehensive hernia care for the state of Delaware and the surrounding areas, and medical personnel should feel very confident that their patients will be well taken care of.”

For patients with uveitis, a rare inflammatory eye disease that can lead to blindness, advances in diagnosis and treatment are allowing for lessened therapeutic burden, with fewer side effects.

“Typically, we think of uveitis as having either infectious or noninfectious causes,” explained Benjamin C. Chaon, MD, medical director of the Wilmington Eye Clinic at ChristianaCare and an ophthalmologist who specializes in treating patients with ocular inflammatory and retinal diseases. “Uveitis can be associated with infections, such as syphilis, toxoplasmosis, or Lyme disease, or it can be noninfectious and associated with an underlying systemic autoimmune disease like sarcoidosis, rheumatoid arthritis, or inflammatory bowel disease. Or, it may not be associated with any underlying systemic disease and just impact the eye, such as Birdshot Chorioretinopathy.”

While the various types of uveitis share the basic feature of inflammation occurring in the vascular structures of the eye, the wide variety of causes can complicate diagnosis.

“The most important distinction we make in the initial diagnosis of uveitis is whether it’s infectious or noninfectious,” Dr. Chaon said. “Sometimes this can be difficult to determine, particularly if a patient develops uveitis following cataract surgery or another type of ocular surgery.”

In recent years, advancements in metagenomic deep-sequencing technology have helped to ease the diagnostic process. This technique allows ophthalmologists to take a small sample of fluid from the front part of the eye during a patient’s clinic visit and conduct testing to determine whether there is the presence of bacteria or fungus.

“This was not always possible in the past, as we often needed larger sample volumes to culture,” Dr. Chaon said. “This was difficult to do from the eye, as it is such a small space. This new technology allows us to more readily make the diagnosis of an infectious uveitic condition. That has been an exciting development in the field of uveitis in the last few years.”

Treatment, too, has advanced, moving beyond the use of corticosteroids. The advent of biologic therapies for the management of uveitis has allowed specialists to significantly decrease their reliance on steroids.

“It used to be that corticosteroids were the mainstay of uveitis treatment, but steroids have a lot of systemic side effects,” Dr. Chaon said. “Biologics are medications we use for patients with other rheumatologic conditions, such as adalimumab or infliximab, which target specific inflammatory molecules. Often these medications are helpful with getting control of the uveitis and allowing us to get patients off of—or to a lower dose of—steroids.”

Advances in regional steroid therapy have also allowed for more targeted treatment options with potentially fewer systemic side effects. For patients with vision-threatening complications of uveitis like macular edema, ophthalmologists historically relied on periocular steroid injections into the sub-Tenon’s space around the eye, with patients often requiring treatment every three to four months.

Recent data from the PeriOcular versus INTravitreal Corticosteroids for uveitic macular edema or “POINT” trial1 has demonstrated that intravitreal delivery of steroid medication directly into the vitreous cavity is superior to periocular steroid injections in the improvement and/or resolution of macular edema.1 Still, patients being treated with an intravitreal steroid medication, like the dexamethasone intravitreal implant (Ozurdex, Allergan), may need injections every few months, which can be quite burdensome, particularly for working-age individuals that uveitis disproportionately effects.

“That’s a lot of injections for patients, and every injection in the eye carries with it a small risk of infection,” Dr. Chaon said.

In contrast, the intravitreal steroid injection Yutiq (fluocinolone, Alimera Sciences) can provide up to 36 months of inflammation control in one dose. Another new medication called Xipere (triamcinolone, Bausch & Lomb) uses a novel drug delivery mechanism to allow the steroid to be injected into the suprachoroidal space—the area between the choroid and the sclera. Research has shown that this approach may result in more effective control of inflammation and a lower risk of increased intraocular pressure.

Although those with uveitis may require regular clinical visits to monitor their disease, reducing the frequency of injections can result in greatly increased patient satisfaction.

“In a lot of cases, uveitis tends to be a chronic disease, and patients do tend to need chronic treatment,” Dr. Chaon said. “So, treatment options that may lessen their treatment burden can be a big relief.”

 

Reference

  1. Thorne JE, Sugar EA, Holbrook JT, et al; Multicenter Uveitis Steroid Treatment Trial Research Group. Ophthalmology. 2019;126(2):283-295.

Refer a Patient/Speak with an Expert

This content is hosted by a third party (Zoho Forms). By showing the external content you accept Zoho's terms and conditions.

Show